Eric Venker sold $1.1M of ROIV
President & COO at Roivant Sciences Ltd.. 100,000 shares at an average of $11.32, traded Nov 20, 2024, filed Nov 22, 2024.
Score components
- +20RolePresident
- +25Trade size$1.1M at market
- +5Share of holdings soldSold 14% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -7.7%, 3m -14.8%, 6m -13.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001140361-24-047697, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 20, 2024 | FTax withholding Common Shares10b5-1 | -10,945 | $11.49 | $126k | 606,525 | Nov 22, 2024 |
| Nov 20, 2024 | MOption exercise Common Shares10b5-1 | +100,000 | $3.85 | $385k | 706,525 | Nov 22, 2024 |
| Nov 20, 2024 | SOpen-market sale Common Shares10b5-1 | -100,000 | $11.32 | $1.1M | 606,525 | Nov 22, 2024 |
| Nov 20, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100,000 | $0.00 | $0 | 12,326,234 | Nov 22, 2024 |
Related signals
Other insiders at Roivant Sciences Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $641k 17,750 shares | -54% | |
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.3M 200,000 shares | -11% | |
| 25Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $196k 4,938 shares | -33% | |
| 20Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $203k 5,112 shares | -12% | |
| 27Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $798k 20,000 shares | -32% | |
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.2M 200,000 shares | -11% | |
| 60Notable | Roivant Sciences Ltd. | Meghan Fitzgerald director | $1.9M 70,000 shares | -62% | |
| 35Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $5.6M 200,000 shares | -11% | |
| 75Notable | Roivant Sciences Ltd. | Epperly Melissa B director | $1.2M 41,861 shares | -73% | |
| 30Weak | Roivant Sciences Ltd. | Frank Torti President and Vant Chair | $82M 3,000,000 shares | -20% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.